[go: up one dir, main page]

NO20000579L - Heparin-bindende vekstfaktor (HBGF) -polypeptider - Google Patents

Heparin-bindende vekstfaktor (HBGF) -polypeptider

Info

Publication number
NO20000579L
NO20000579L NO20000579A NO20000579A NO20000579L NO 20000579 L NO20000579 L NO 20000579L NO 20000579 A NO20000579 A NO 20000579A NO 20000579 A NO20000579 A NO 20000579A NO 20000579 L NO20000579 L NO 20000579L
Authority
NO
Norway
Prior art keywords
polypeptides
hbgf
growth factor
heparin
hbgfs
Prior art date
Application number
NO20000579A
Other languages
English (en)
Other versions
NO20000579D0 (no
Inventor
David A Brigstock
Paul A Harding
Original Assignee
Childrens Hosp Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp Res Foundation filed Critical Childrens Hosp Res Foundation
Publication of NO20000579D0 publication Critical patent/NO20000579D0/no
Publication of NO20000579L publication Critical patent/NO20000579L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Hovedsakelig rene heparin-bindende vekstfaktorpolypeptider (HBGF'er), nukleinsyrer som koder for HBGF'ene og antistoffer som binder til HBGF'ene i den foreliggende oppfinnelsen er tilveiebragt. HBGF-polypeptidene er nyttige i fremgangsmåter for induksjon av ben-, brusk- og vevsdannelse, vekst og utvikling av endometriet og for å akselerere sårtilheling.
NO20000579A 1997-08-07 2000-02-04 Heparin-bindende vekstfaktor (HBGF) -polypeptider NO20000579L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/908,526 US5876730A (en) 1997-08-07 1997-08-07 Heparin-binding growth factor (HBGF) polypeptides
PCT/US1998/016423 WO1999007407A1 (en) 1997-08-07 1998-08-06 Heparin-binding growth factor (hbgf) polypeptides

Publications (2)

Publication Number Publication Date
NO20000579D0 NO20000579D0 (no) 2000-02-04
NO20000579L true NO20000579L (no) 2000-02-25

Family

ID=25425931

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000579A NO20000579L (no) 1997-08-07 2000-02-04 Heparin-bindende vekstfaktor (HBGF) -polypeptider

Country Status (15)

Country Link
US (3) US5876730A (no)
EP (1) EP1003545B1 (no)
JP (2) JP4638027B2 (no)
CN (1) CN1276729A (no)
AT (1) ATE395927T1 (no)
AU (1) AU744585B2 (no)
BR (1) BR9811861A (no)
CA (1) CA2299411A1 (no)
DE (1) DE69839516D1 (no)
DK (1) DK1003545T3 (no)
ES (1) ES2307322T3 (no)
IL (1) IL134330A0 (no)
NO (1) NO20000579L (no)
PT (1) PT1003545E (no)
WO (1) WO1999007407A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043335A4 (en) 1997-12-25 2005-08-31 Japan Tobacco Inc MONOCLONAL ANTIBODY AGAINST THE BIND WEIGHT GROWTH FACTOR AND ITS MEDICAL USES
US7141384B1 (en) 1998-10-06 2006-11-28 Georgetown University Detection of pleiotrophin
WO2000020869A1 (en) * 1998-10-06 2000-04-13 Georgetown University Detection of pleiotrophin
ATE391724T1 (de) * 1998-12-14 2008-04-15 Univ Miami FRAGMENT DES ßCONNECTIVE TISSUE GROWTH FACTORß (CTGF)
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
AU2001288392A1 (en) 2000-08-30 2002-03-13 University Of Delaware Delivery system for heparin-binding growth factors
US7297343B2 (en) * 2001-07-31 2007-11-20 Biosurface Engineering Technologies, Inc. Bioactive medical films
FR2828104B1 (fr) * 2001-08-01 2005-06-24 Chu Montpellier Utilisation d'inhibiteurs du facteur de croissance epidermique liant l'heparine ou d'inhibiteurs de ses recepteurs pour la preparation de medicaments utiles pour traiter le myelome
AU2002326939A1 (en) * 2001-09-18 2003-04-01 Fibrogen, Inc. Methods of assaying connective tissue growth factor
US6965025B2 (en) * 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
GB0225197D0 (en) * 2002-10-30 2002-12-11 Univ Sheffield Surface
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
WO2005033136A1 (en) * 2003-09-29 2005-04-14 Children's Hospital, Inc. Unique integrin binding site in connective tissue growth factor (ctgf)
PL1715890T3 (pl) 2004-02-11 2009-01-30 Fibrogen Inc CTGF jako cel dla terapii mikroalbinurii u pacjentów z nefropatią cukrzycową
US20050271670A1 (en) 2004-04-28 2005-12-08 Spong Suzanne M Treatments for cancer
DE102004021872B3 (de) 2004-05-04 2005-12-22 Infineon Technologies Ag Chipkarte, Verfahren zum Herstellen einer Chipkarte und elektrisch leitfähiges Kontaktierungselement
US20070049739A1 (en) * 2005-08-30 2007-03-01 Biomet Manufacturing Corp. Method and system for extracting blood-derived growth factors
WO2010042281A2 (en) 2008-08-25 2010-04-15 Excaliard Pharmaceuticals Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US8946172B2 (en) * 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
CN101497656B (zh) * 2009-03-09 2012-08-15 东南大学 与整合素αvβ3具有高结合活性的多肽及其应用
WO2011002525A1 (en) 2009-07-02 2011-01-06 Fibrogen, Inc. Methods for treatment of muscular dystrophy
US9102721B2 (en) 2011-01-21 2015-08-11 Fibrogen, Inc. Therapeutic method
BR112013019803A2 (pt) 2011-02-02 2019-06-11 Excaliard Pharmaceuticals Inc método de tratar quelóides ou cicatrizes hipertróficas usando os compostos anti-sentido objetivando fator de desenvolvimento de tecido conjuntivo (ctgf)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235042A (en) * 1984-02-29 1993-08-10 The Children's Medical Center Corporation Endothelial cell growth factor
US4868113A (en) * 1986-03-03 1989-09-19 Rorer Biotechnology, Inc. Recombinant DNA vector encoding human endothelial cell growth factor
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85018A0 (en) * 1988-01-03 1988-06-30 Orgenics Ltd Stable chromogenic substrate mixture of indoxyl phosphate and tetrazolium salt,method of making and using same in biological and diagnostic assays
US5225326A (en) * 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
EP0559769B1 (en) 1990-10-16 2001-02-07 The Children's Medical Center Corporation Heparin binding mitogen with homology to epidermal growth factor (egf)
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5596090A (en) * 1992-07-24 1997-01-21 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human VCAM-1 RNA
EP0804562B1 (en) 1994-07-12 2002-10-09 Human Genome Sciences, Inc. Connective tissue growth factor-2
US5646115A (en) * 1994-10-07 1997-07-08 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof

Also Published As

Publication number Publication date
ES2307322T3 (es) 2008-11-16
US7897732B2 (en) 2011-03-01
EP1003545A4 (en) 2002-03-06
CA2299411A1 (en) 1999-02-18
WO1999007407A9 (en) 1999-05-06
US20110160445A1 (en) 2011-06-30
EP1003545A1 (en) 2000-05-31
JP4638027B2 (ja) 2011-02-23
EP1003545B1 (en) 2008-05-21
CN1276729A (zh) 2000-12-13
US5876730A (en) 1999-03-02
AU8696298A (en) 1999-03-01
WO1999007407A1 (en) 1999-02-18
US20010007019A1 (en) 2001-07-05
JP2009254370A (ja) 2009-11-05
ATE395927T1 (de) 2008-06-15
DE69839516D1 (de) 2008-07-03
DK1003545T3 (da) 2008-08-25
BR9811861A (pt) 2000-08-15
JP2001513334A (ja) 2001-09-04
NO20000579D0 (no) 2000-02-04
IL134330A0 (en) 2001-04-30
AU744585B2 (en) 2002-02-28
PT1003545E (pt) 2008-08-13

Similar Documents

Publication Publication Date Title
NO20000579L (no) Heparin-bindende vekstfaktor (HBGF) -polypeptider
NO995044D0 (no) Osteoprotegerinbindende proteiner og reseptorer
MX9206315A (es) Heterodimeros recombinantes de proteinas morfogenicas de hueso, composiciones de estos y metodos para su uso.
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
CY1112101T1 (el) Νευροτροφικοι παραγοντες
NZ330897A (en) Human trk receptors and neurotropic factor inhibitors
ATE265529T1 (de) Bmp-10 zusammensetzungen
DE69032598D1 (de) Zusammensetzungen und methoden zur synthese des b-rezeptors für das natriuretische protein und verwendungsmethoden
DE69535855D1 (de) Calciumbindende rekombinante antikörper gegen protein c
PT783521E (pt) Compostos polipeptidos que contem d-2-alquiltriptofano capazes de promover a libertacao da hormona do crescimento
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
DE19781038T1 (de) Keratinozytenwachstumsfaktor-2-Produkte
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
ATE161543T1 (de) Aminoterminale prokollagen 1(i) peptide
DE59814002D1 (de) Sekretion von tragergebundenen proteinen in das periplasma und in den extrazellulären raum
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
SE9604439D0 (sv) New receptor
EA200100110A1 (ru) Нейротрофические факторы
ATE328088T1 (de) Transketolase-verwandtes protein

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application